Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1422) 1422
Publication (100) 100
Book Review (62) 62
Book Chapter (22) 22
Book / eBook (6) 6
Magazine Article (6) 6
Dissertation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1246) 1246
female (1126) 1126
selective estrogen receptor modulators - therapeutic use (694) 694
index medicus (573) 573
selective estrogen receptor modulators - adverse effects (557) 557
middle aged (475) 475
postmenopausal women (430) 430
aged (342) 342
tamoxifen (333) 333
raloxifene (319) 319
estrogen (303) 303
animals (279) 279
selective estrogen receptor modulators - pharmacology (276) 276
tamoxifen - therapeutic use (271) 271
tamoxifen - adverse effects (268) 268
breast neoplasms - drug therapy (266) 266
raloxifene hydrochloride - therapeutic use (263) 263
osteoporosis (261) 261
breast cancer (247) 247
obstetrics & gynecology (245) 245
risk factors (225) 225
hormone replacement therapy (221) 221
postmenopause (216) 216
adult (215) 215
oncology (214) 214
pharmacology & pharmacy (202) 202
selective estrogen receptor modulators - administration & dosage (202) 202
raloxifene hydrochloride - adverse effects (200) 200
breast neoplasms - prevention & control (196) 196
breast-cancer (188) 188
menopause (178) 178
treatment outcome (176) 176
selective estrogen receptor modulators (174) 174
osteoporosis, postmenopausal - drug therapy (170) 170
risk (170) 170
prevention (155) 155
bone-mineral density (152) 152
women (151) 151
male (145) 145
endocrinology & metabolism (132) 132
double-blind method (131) 131
estrogen replacement therapy - adverse effects (124) 124
randomized controlled trials as topic (124) 124
antineoplastic agents, hormonal - therapeutic use (121) 121
cancer (120) 120
antineoplastic agents, hormonal - adverse effects (119) 119
osteoporosis, postmenopausal - prevention & control (119) 119
health aspects (118) 118
randomized-trial (117) 117
selective estrogen receptor modulator (115) 115
raloxifene hydrochloride - pharmacology (110) 110
clinical trials as topic (108) 108
care and treatment (107) 107
research (104) 104
bone density - drug effects (103) 103
medicine, general & internal (100) 100
drug therapy (98) 98
bone density conservation agents - therapeutic use (96) 96
therapy (96) 96
osteoporosis - drug therapy (94) 94
aged, 80 and over (89) 89
bazedoxifene (89) 89
tamoxifen - pharmacology (88) 88
double-blind (87) 87
raloxifene hydrochloride - administration & dosage (86) 86
risk assessment (86) 86
medicine & public health (85) 85
breast neoplasms - pathology (84) 84
surgical adjuvant breast (81) 81
dose-response relationship, drug (78) 78
estrogens (78) 78
tamoxifen - administration & dosage (77) 77
aromatase inhibitors (75) 75
internal medicine (74) 74
randomized controlled-trial (74) 74
diphosphonates - therapeutic use (72) 72
endometrium - drug effects (72) 72
receptors, estrogen - metabolism (72) 72
serm (71) 71
vertebral fracture risk (70) 70
estrogen replacement therapy (69) 69
rats (68) 68
aromatase inhibitors - therapeutic use (67) 67
indoles - adverse effects (67) 67
healthy postmenopausal women (66) 66
tamoxifen - analogs & derivatives (65) 65
endometrial neoplasms - chemically induced (63) 63
endometrium (63) 63
quality of life (63) 63
bone density (61) 61
endometrial cancer (61) 61
trial (61) 61
bone density conservation agents - adverse effects (60) 60
breast neoplasms - epidemiology (60) 60
estrogens - adverse effects (60) 60
review (60) 60
analysis (59) 59
indoles - therapeutic use (59) 59
quality-of-life (59) 59
article (58) 58
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1337) 1337
Japanese (41) 41
French (21) 21
German (15) 15
Spanish (12) 12
Danish (5) 5
Polish (5) 5
Dutch (4) 4
Italian (4) 4
Hungarian (3) 3
Russian (3) 3
Portuguese (2) 2
Arabic (1) 1
Czech (1) 1
Finnish (1) 1
Hebrew (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
by Early Breast Cancer Trialists' Collaborative Group (EBCTCG) and EBCTCG and Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9793, pp. 771 - 784
Summary Background As trials of 5 years of tamoxifen in early breast cancer mature, the relevance of hormone receptor measurements (and other patient... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | POSTMENOPAUSAL | THERAPY | HIGH-RISK | DOXORUBICIN | RECURRENCE | PREMENOPAUSAL WOMEN | PROGESTERONE-RECEPTOR | ESTROGEN-RECEPTOR | CHEMOTHERAPY | IMMUNOHISTOCHEMISTRY | Receptors, Estrogen - metabolism | Neoplasm Recurrence, Local - prevention & control | Humans | Selective Estrogen Receptor Modulators - adverse effects | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Randomized Controlled Trials as Topic | Receptors, Progesterone - metabolism | Antineoplastic Agents, Hormonal - adverse effects | Selective Estrogen Receptor Modulators - therapeutic use | Breast Neoplasms - pathology | Neoplasms, Second Primary - chemically induced | Antineoplastic Agents, Hormonal - therapeutic use | Tamoxifen - therapeutic use | Breast Neoplasms - mortality | Female | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Patient outcomes | Breast cancer | Research | Diagnosis | Tamoxifen | Drug therapy | Health aspects | Chemotherapy | Compliance | Womens health | Mortality | Endocrine therapy | Data collection | Stratigraphy | Cancer therapies | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile
by Lobo, Rogerio A., M.D and Pinkerton, JoAnn V., M.D and Gass, Margery L.S., M.D and Dorin, Maxine H., M.D and Ronkin, Sheila, M.D and Pickar, James H., M.D and Constantine, Ginger, M.D
Fertility and Sterility, ISSN 0015-0282, 2009, Volume 92, Issue 3, pp. 1025 - 1038
Objective To evaluate the effects of a tissue-selective estrogen complex (TSEC) composed of bazedoxifene/conjugated estrogens (BZA/CE) on menopausal symptoms,... 
Internal Medicine | Obstetrics and Gynecology | breast pain | Bazedoxifene | hot flushes | metabolism | vaginal atrophy | conjugated estrogens | coagulation | PLACEBO | RISK-FACTORS | MEDROXYPROGESTERONE ACETATE | OSTEOPOROSIS | OBSTETRICS & GYNECOLOGY | TRIAL | REPRODUCTIVE BIOLOGY | DISEASE | POSTMENOPAUSAL WOMEN | RECEPTOR MODULATOR | LIPIDS | Carbohydrate Metabolism - drug effects | Estrogens, Conjugated (USP) - pharmacology | Estrogens - pharmacology | Vagina - drug effects | Humans | Middle Aged | Atrophy - pathology | Selective Estrogen Receptor Modulators - adverse effects | Homocysteine - metabolism | Estrogens - adverse effects | Estrogens - therapeutic use | Dose-Response Relationship, Drug | Menopause - drug effects | Selective Estrogen Receptor Modulators - therapeutic use | Adult | Female | Indoles - pharmacology | Atrophy - drug therapy | Drug Therapy, Combination | Vagina - pathology | Hot Flashes - drug therapy | Double-Blind Method | Treatment Outcome | Estrogens, Conjugated (USP) - therapeutic use | Indoles - adverse effects | Menopause - metabolism | Outpatients | Lipid Metabolism - drug effects | Indoles - therapeutic use | Aged | Estrogens, Conjugated (USP) - adverse effects | Selective Estrogen Receptor Modulators - pharmacology | Benzoic acid | Women | Medical colleges | Care and treatment | Safety and security measures | Analysis | Menopause | Estrogen | Health aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice
by Maximov, Philipp Y and Lee, Theresa M and Craig Jordan, V
Current Clinical Pharmacology, ISSN 1574-8847, 2013, Volume 8, Issue 2, pp. 135 - 155
Selective estrogen receptor modulators (SERMs) are structurally different compounds that interact with intracellular estrogen receptors in target organs as... 
Arzoxifene | Ospemifene | Selective estrogen receptor modulator | Bazedoxifene | Lasofoxifene | Raloxifene | Tamoxifen | Humans | Selective Estrogen Receptor Modulators - adverse effects | Osteoporosis, Postmenopausal - pathology | Clinical Trials as Topic | Breast Neoplasms - drug therapy | Drug Discovery | Osteoporosis, Postmenopausal - drug therapy | Animals | Selective Estrogen Receptor Modulators - therapeutic use | Breast Neoplasms - pathology | Drug Design | Female | Osteoporosis, Postmenopausal - prevention & control | Selective Estrogen Receptor Modulators - pharmacology
Journal Article
Details down arrow
4. Full Text Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy
by Pickar, James H., M.D and Yeh, I-Tien, M.D and Bachmann, Gloria, M.D and Speroff, Leon, M.D
Fertility and Sterility, ISSN 0015-0282, 2009, Volume 92, Issue 3, pp. 1018 - 1024
Objective To evaluate the endometrial safety of a tissue selective estrogen complex (TSEC; pairing of a selective estrogen receptor modulator [SERM] with... 
Internal Medicine | Obstetrics and Gynecology | endometrium | hyperplasia | tissue-selective estrogen complex | B azedoxifene | TSEC | conjugated estrogens | CONJUGATED EQUINE ESTROGENS | RALOXIFENE | MEDROXYPROGESTERONE ACETATE | OBSTETRICS & GYNECOLOGY | REPRODUCTIVE BIOLOGY | POSTMENOPAUSAL WOMEN | RECEPTOR MODULATOR | CARCINOMA | Estrogens, Conjugated (USP) - pharmacology | Postmenopause - drug effects | Estrogens - pharmacology | Humans | Middle Aged | Endometrium - drug effects | Selective Estrogen Receptor Modulators - adverse effects | Estrogens - adverse effects | Endometrial Neoplasms - prevention & control | Estrogens - therapeutic use | Dose-Response Relationship, Drug | Selective Estrogen Receptor Modulators - therapeutic use | Adult | Female | Indoles - pharmacology | Drug Therapy, Combination | Endometrial Hyperplasia - prevention & control | Double-Blind Method | Treatment Outcome | Estrogens, Conjugated (USP) - therapeutic use | Receptors, Estrogen - drug effects | Indoles - adverse effects | Outpatients | Indoles - therapeutic use | Aged | Endometrium - pathology | Estrogens, Conjugated (USP) - adverse effects | Selective Estrogen Receptor Modulators - pharmacology | Benzoic acid | Phenols | Postmenopausal women | Menopause | Estrogen | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Selective estrogen receptor modulators (SERMs) for uterine leiomyomas
by Deng, Linyu and Wu, Taixiang and Chen, Xiao Y and Xie, Lingxia and Yang, Jinrong
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2012, Volume 10, Issue 10, p. CD005287
Background Uterine fibroids are benign tumours that arise from individual smooth muscle cells of the uterus. Selective estrogen receptor modulators (SERMs) are... 
ETIOLOGY | Leuprolide [adverse effects; therapeutic use] | ENDOMETRIUM | RALOXIFENE | Humans | Leiomyoma [drug therapy] | Raloxifene [adverse effects; therapeutic use] | Selective Estrogen Receptor Modulators [adverse effects; therapeutic use] | Randomized Controlled Trials as Topic | MEDICINE, GENERAL & INTERNAL | ESTRADIOL | Female | Uterine Neoplasms [drug therapy] | POSTMENOPAUSAL WOMEN | HORMONE AGONIST | BINDING | FIBROIDS | ADVERSE EVENTS | Raloxifene Hydrochloride - adverse effects | Raloxifene Hydrochloride - therapeutic use | Selective Estrogen Receptor Modulators - adverse effects | Young Adult | Selective Estrogen Receptor Modulators - therapeutic use | Leiomyoma - drug therapy | Leuprolide - therapeutic use | Uterine Neoplasms - drug therapy | Adult | Leuprolide - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Selective estrogen receptor modulators: Tissue specificity and clinical utility
by Martinkovich, Stephen and Shah, Darshan and Planey, Sonia Lobo and Arnott, John A
Clinical Interventions in Aging, ISSN 1176-9092, 09/2014, Volume 9, pp. 1437 - 1452
Selective estrogen receptor modulators (SERMs) are a diverse group of nonsteroidal compounds that function as agonists or antagonists for estrogen receptors... 
SERMs | Estrogen receptors | Selective estrogen receptor modulators | selective estrogen receptor modulators | SURGICAL ADJUVANT BREAST | PHASE-II | estrogen receptors | ENDOMETRIAL CANCER | GERIATRICS & GERONTOLOGY | BAZEDOXIFENE ACETATE | VERTEBRAL FRACTURE RISK | METASTATIC BREAST-CANCER | TAMOXIFEN-DNA ADDUCTS | POSTMENOPAUSAL WOMEN | PREVENTS BONE LOSS | STEROID-HORMONE RECEPTORS | Selective Estrogen Receptor Modulators - adverse effects | Female | Selective Estrogen Receptor Modulators - therapeutic use | Organ Specificity | Humans | Chronic diseases | Receptors | Pharmacology, Experimental | Health aspects | Risk factors | Estrogen | Disease prevention | Osteoporosis | Endometrial cancer | Metabolites | Womens health | Genes | Ligands | Breast cancer | Deoxyribonucleic acid--DNA | Selective Estrogen Receptor Modulators
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators
by Xie, Lei and Wang, Jian and Bourne, Philip E
PLoS Computational Biology, ISSN 1553-734X, 11/2007, Volume 3, Issue 11, pp. 2324 - 2332
Early identification of adverse effect of preclinical and commercial drugs is crucial in developing highly efficient therapeutics, since unexpected adverse... 
CARDIAC SARCOPLASMIC-RETICULUM | LIGAND-BINDING | CHEMICAL-STRUCTURE | BREAST-CANCER DRUG | LENS EPITHELIAL-CELLS | INTRACELLULAR CALCIUM | CRYSTAL-STRUCTURE | TAMOXIFEN | DOCKING | BIOCHEMICAL RESEARCH METHODS | MATHEMATICAL & COMPUTATIONAL BIOLOGY | SCORING FUNCTIONS | Amino Acid Sequence | Sequence Analysis, Protein - methods | Models, Chemical | Models, Molecular | Molecular Sequence Data | Selective Estrogen Receptor Modulators - adverse effects | Selective Estrogen Receptor Modulators - chemistry | Structure-Activity Relationship | Protein Interaction Mapping - methods | Receptors, Estrogen - chemistry | Computer Simulation | Protein Binding | Protein Conformation | Toxicity Tests - methods | Binding Sites | Biotechnology | Oncology | Biophysics | Homo (Human) | Computational Biology | Proteins | Research & development | Case studies | R&D | Integrated approach | Rodents | Estrogen | Ligands | Pharmaceutical industry | Gene expression | Binding sites
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Effects of Bazedoxifene/Conjugated Estrogens on the Endometrium and Bone: A Randomized Trial
by Pinkerton, JoAnn V and Harvey, Jennifer A and Lindsay, Robert and Pan, Kaijie and Chines, Arkadi A and Mirkin, Sebastian and Archer, David F and SMART-5 Investigators and for the SMART-5 Investigators
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 02/2014, Volume 99, Issue 2, pp. E189 - E198
Objective: This phase 3 study evaluated the endometrial safety of bazedoxifene (BZA)/conjugated estrogens (CE) and bone mineral density (BMD) effects vs BZA... 
CLINICAL-TRIAL | VERTEBRAL FRACTURE RISK | VULVAR/VAGINAL ATROPHY | MEDROXYPROGESTERONE ACETATE | ENDOCRINOLOGY & METABOLISM | MENOPAUSAL SYMPTOMS | VAGINAL ATROPHY | CONJUGATED ESTROGENS | HORMONE REPLACEMENT THERAPY | POSTMENOPAUSAL WOMEN | OSTEOPOROSIS | Estrogens, Conjugated (USP) - pharmacology | Humans | Middle Aged | Endometrium - drug effects | Medroxyprogesterone Acetate - pharmacology | Selective Estrogen Receptor Modulators - adverse effects | Selective Estrogen Receptor Modulators - therapeutic use | Medroxyprogesterone Acetate - adverse effects | Adult | Female | Indoles - pharmacology | Endometrial Hyperplasia - chemically induced | Drug Therapy, Combination | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Medroxyprogesterone Acetate - therapeutic use | Bone Density Conservation Agents - therapeutic use | Treatment Outcome | Lumbar Vertebrae - drug effects | Bone Density Conservation Agents - pharmacology | Estrogens, Conjugated (USP) - therapeutic use | Bone Density - drug effects | Indoles - adverse effects | Indoles - therapeutic use | Aged | Estrogens, Conjugated (USP) - adverse effects | Selective Estrogen Receptor Modulators - pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Selective estrogen receptor modulators in clinical practice: a safety overview
by Ellis, Amanda J and Hendrick, Vicky M and Williams, Robert and Komm, Barry S
Expert Opinion on Drug Safety, ISSN 1474-0338, 06/2015, Volume 14, Issue 6, pp. 921 - 934
Introduction: Selective estrogen receptor (ER) modulators (SERMs) are a class of nonsteroidal compounds that interact with ERs, each with a distinct... 
bazedoxifene | fulvestrant | safety | toremifene | selective estrogen receptor modulator | raloxifene | lasofoxifene | ospemifene | tamoxifen | Ospemifene | Selective estrogen receptor modulator | Bazedoxifene | Lasofoxifene | Toremifene | Raloxifene | Safety | Tamoxifen | Fulvestrant | PEARL TRIAL | ADVANCED BREAST-CANCER | SURGICAL ADJUVANT BREAST | CARDIOVASCULAR EVENTS | PHASE-III | RANDOMIZED-TRIAL | VERTEBRAL FRACTURE RISK | DOUBLE-BLIND | VAGINAL ATROPHY | PHARMACOLOGY & PHARMACY | POSTMENOPAUSAL OSTEOPOROTIC WOMEN | Dyspareunia - drug therapy | Humans | Selective Estrogen Receptor Modulators - adverse effects | Estrogens - adverse effects | Breast Neoplasms - drug therapy | Osteoporosis, Postmenopausal - drug therapy | Estrogens - therapeutic use | Patient Selection | Estrogen Antagonists - therapeutic use | Selective Estrogen Receptor Modulators - therapeutic use | Estrogen Antagonists - adverse effects | Female | Drug Monitoring
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Selective estrogen receptor modulator-associated nonalcoholic fatty liver disease improved survival in patients with breast cancer a retrospective cohort analysis
by Zheng, Qiufan and Xu, Fei and Nie, Man and Xia, Wen and Qin, Tao and Qin, Ge and An, Xin and Xue, Cong and Peng, Roujun and Yuan, Zhongyu and Shi, Yanxia and Wang, Shusen
Medicine (United States), ISSN 0025-7974, 10/2015, Volume 94, Issue 40, p. e1718
Selective estrogen receptor modulator (SERM)-associated nonalcoholic fatty liver disease (NAFLD) might be related to treatment efficacy in patients with breast... 
INSULIN | TOREMIFENE | MEDICINE, GENERAL & INTERNAL | NEGATIVE-RISK-FACTOR | ADJUVANT TAMOXIFEN | MONOCLONAL-ANTIBODY | COMBINATION | IGF-1R | FACTOR-I RECEPTOR | HEPATIC STEATOSIS | EXPRESSION | Non-alcoholic Fatty Liver Disease - diagnostic imaging | Prognosis | Humans | Middle Aged | Selective Estrogen Receptor Modulators - adverse effects | Breast Neoplasms - drug therapy | Regression Analysis | Non-alcoholic Fatty Liver Disease - chemically induced | Selective Estrogen Receptor Modulators - therapeutic use | Tamoxifen - therapeutic use | Toremifene - therapeutic use | Survival Analysis | Ultrasonography | Aged, 80 and over | Adult | Breast Neoplasms - mortality | Female | Toremifene - adverse effects | Aged | Retrospective Studies | Tamoxifen - adverse effects | Care and treatment | Receptors | Fatty liver | Analysis | Estrogen | Breast cancer | Dosage and administration | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Soy Isoflavones--Benefits and Risks from Nature's Selective Estrogen Receptor Modulators (SERMs)
by Setchell, Kenneth D. R
Journal of the American College of Nutrition, ISSN 0731-5724, 10/2001, Volume 20, Issue Supplement 5, pp. 354 - 362S
Phytoestrogens have become one of the more topical areas of interest in clinical nutrition. These non-nutrient bioactive compounds are ubiquitous to the plant... 
pharmacokinetics | phytoestrogens | phytoprotectants | soy isoflavones | Phytoprotectants | Phytoestrogens | Soy isoflavones | Pharmacokinetics | SYSTEMIC ARTERIAL COMPLIANCE | HUMAN HEALTH | LOW-DENSITY-LIPOPROTEIN | BREAST-CANCER | NON-STEROIDAL ESTROGEN | BETA-GLUCOSIDASE ACTIVITY | NUTRITION & DIETETICS | BONE LOSS | HUMAN-URINE | POSTMENOPAUSAL WOMEN | DIETARY PHYTOESTROGENS | Selective Estrogen Receptor Modulators - pharmacokinetics | Humans | Isoflavones - pharmacokinetics | Selective Estrogen Receptor Modulators - adverse effects | Biological Availability | Selective Estrogen Receptor Modulators - administration & dosage | Intestinal Absorption | Soybeans - chemistry | Estrogens, Non-Steroidal - administration & dosage | Plant Preparations | Estrogens, Non-Steroidal - pharmacokinetics | Isoflavones - adverse effects | Estrogens, Non-Steroidal - adverse effects | Safety | Isoflavones - administration & dosage
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Systematic Review: Comparative Effectiveness of Treatments to Prevent Fractures in Men and Women with Low Bone Density or Osteoporosis
by Catherine MacLean and Sydne Newberry and Margaret Maglione and Maureen McMahon and Veena Ranganath and Marika Suttorp and Walter Mojica and Martha Timmer and Alicia Alexander and Melissa McNamara and Sheetal B. Desai and Annie Zhou and Susan Chen and Jason Carter and Carlo Tringale and Di Valentine and Breanne Johnsen and Jennifer Grossman
Annals of Internal Medicine, ISSN 0003-4819, 02/2008, Volume 148, Issue 3, pp. 197 - 213
Background: Although several agents are available to treat osteoporosis, the relative efficacy and toxicity of these agents when used to prevent fractures has... 
VITAMIN-D SUPPLEMENTATION | MEDICINE, GENERAL & INTERNAL | EARLY POSTMENOPAUSAL WOMEN | PRIMARY BILIARY-CIRRHOSIS | CYCLICAL ETIDRONATE THERAPY | ONCE-WEEKLY ALENDRONATE | RANDOMIZED CONTROLLED-TRIAL | PLACEBO-CONTROLLED TRIAL | CORTICOSTEROID-INDUCED OSTEOPOROSIS | HORMONE REPLACEMENT THERAPY | ESTROGEN PLUS PROGESTIN | Bone Density | Bone Density Conservation Agents - adverse effects | Humans | Risk Factors | Bone Density Conservation Agents - therapeutic use | Selective Estrogen Receptor Modulators - adverse effects | Male | Estrogens - adverse effects | Estrogen Replacement Therapy - adverse effects | Estrogens - therapeutic use | Vitamin D - adverse effects | Calcium - adverse effects | Fractures, Bone - etiology | Selective Estrogen Receptor Modulators - therapeutic use | Calcium - therapeutic use | Osteoporosis - complications | Androgens - therapeutic use | Female | Testosterone - adverse effects | Androgens - adverse effects | Vitamin D - therapeutic use | Fractures, Bone - prevention & control | Testosterone - therapeutic use | Prevention | Osteoporosis | Fractures | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights